Khartis is a drug discovery company developing oral therapies for immune-mediated and chronic diseases, with a focus on treatments and care.
Khartis Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in August 2026.
Khartis Therapeutics's investors include Longwood Fund, Foresite Capital, Lilly Asia Ventures, Alexandria Venture Investments, Forge Life Science Partners.
Khartis Therapeutics is headquartered in San Diego, United States.
Khartis is a drug discovery company developing oral therapies for immune-mediated and chronic diseases, with a focus on treatments and care.
Khartis Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Khartis Therapeutics — Funding & Investors." VCBacked, August 13, 2026, https://www.vcbacked.co/company/khartis-therapeutics. Accessed September 1, 2026.
VCBacked. (2026). Khartis Therapeutics — Funding & Investors. Retrieved September 1, 2026, from https://www.vcbacked.co/company/khartis-therapeutics
{{cite web |title=Khartis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/khartis-therapeutics |website=VCBacked |access-date=September 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated